A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

Key Findings

Semaglutide 2.4 mg Works in Chinese Adults — With a Smaller BMI Threshold 🇨🇳

• The STEP 12 trial tested once-weekly semaglutide 2.4 mg in adults from mainland China and Taiwan using locally defined BMI cutoffs — lower than Western thresholds — and confirmed meaningful weight loss and cardiometabolic benefit.
• This matters because most landmark GLP-1 trials enrolled predominantly Western populations. STEP 12 fills a real evidence gap for one of the world's largest patient pools.

Tirzepatide May Reduce Carpal Tunnel Risk — Not Just Waistlines

• A retrospective study of U.S. adults found tirzepatide users had a 18-25% lower risk of carpal tunnel syndrome compared to other anti-obesity medications, and a 36% lower risk of needing surgery versus non-GLP-1 alternatives.
• The association was strongest against non-GLP-1 drugs, suggesting either metabolic or neuroprotective effects beyond weight loss alone — though the study can't prove cause and effect.

GLP-1 Drugs Don't Appear to Raise Depression Risk — But the Data Is Messy

• A meta-analysis of semaglutide studies found no statistically significant increase in depression, anxiety, or suicidal ideation compared to placebo or other treatments. The pooled risk ratio for depression was 1.25 — elevated in direction but not statistically significant.
• The caveat is loud: heterogeneity across studies was extremely high, and many data sources relied on spontaneous adverse event reports. This is reassuring, not definitive.

Tirzepatide Beats Insulin on Liver Fat — Regardless of a Common Genetic Variant

• A post-hoc analysis of the SURPASS-3 MRI trial found tirzepatide reduced liver fat content significantly versus insulin degludec in type 2 diabetes patients — and the benefit held whether or not patients carried the PNPLA3 gene variant strongly linked to fatty liver disease.
• That variant affects roughly a third of people with liver fat accumulation. The finding suggests tirzepatide's liver benefit isn't genetically gated, which broadens its potential relevance.

GLP-1 Drugs Shift Healthcare Spending — They Don't Save Money Yet

• An analysis of U.S. insurance data found GLP-1 users had fewer hospital admissions and lower acute-care costs, but total medical spending was still higher by roughly $6,400 per person per year — because drug costs dominate.
• The pattern looks like a reallocation: less inpatient care, more pharmacy spend. Whether that trade-off pays off over a longer horizon isn't answered by same-year claims data.

Using GLP-1 Drugs Before Bariatric Surgery: Does It Hurt Outcomes After? 🔪

• A JAMA Surgery cohort study examined whether taking a GLP-1 drug before bariatric surgery changed post-surgical weight loss outcomes. Preoperative GLP-1 use was the exposure; post-surgical weight loss was the outcome.
• This question matters because more patients are arriving at surgery having already lost weight on these drugs — and surgeons need to know whether that changes the calculus. The study adds real-world data to a mostly theoretical debate.